NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Astrazeneca von 13000 auf 12500 Pence gesenkt, aber…
Barclays updates FTSE stock targets, AstraZeneca and Admiral rise…
…
Could AstraZeneca be an under-rated buy right now?…
Could AstraZeneca be an under-rated buy right now?…
Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…
…
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Evinova wird als eigenständiger Health-Tech-Geschäftsbereich innerhalb von…
J&Js (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on…
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical…
Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)s shares, recommending an "overweight" position with a target price…
AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with…
It might have a hard time finding a home in the market.…
The CDCs move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise…
17 November 2023
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
First-in-class AKT inhibitor has potential to reshape…
FDA approves AstraZenecas (AZN) new breast cancer drug, Truqap, and the expanded use of Mercks (MRK) Keytruda in a gastric…
AstraZenecas (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.…
…
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that,…
AstraZenecas (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.…
CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem seiner Kassenschlager erlitten. Eine…
CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem…
Im Wertpapierhandel ist der Anteilsschein von AstraZeneca zur Stunde unauffällig. Die Aktie notiert derzeit bei 63,37 US-Dollar. Der heutige Börsentag…
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
…
"The incumbent almost always wins," Jim Cramer said this week.…
AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.…
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral…
AZN earnings call for the period ending September 30, 2023.…
…
…
AstraZeneca is the latest player to enter the weight loss drug market, which analysts predict could reach $100 billion by…
AstraZeneca CFO Aradhana Sarin discusses the companys third-quarter results and its plans to develop an obesity pill. The treatment developed…
The FTSE 100 gained on Thursday as macroeconomic concerns took a back seat and investors focused on corporate earnings. Upbeat…
9 November 2023 15:00 BST
Director Declaration
AstraZeneca PLC (the Company) today announced that Philip Broadley,senior independent Non-Executive Directorof the Company, has…
The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.…
AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year in the hope that its foray into a semaglutide…
AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide…
London (Reuters) - Der britische Pharmakonzern AstraZeneca erhöht dank starker Nachfrage nach seinen Krebsmedikamenten die Geschäftsziele für dieses Jahr.
Inmitten…
CAMBRIDGE (dpa-AFX) - Astrazeneca hat den Umsatzschwund bei Covid-Arzneien auch im dritten Quartal gut verkraftet. Der britisch-schwedische Pharmakonzern profitierte…
(Korrigiert wird im Text die Währung. Astrazeneca berichtet in US-Dollar rpt US-Dollar.)
CAMBRIDGE…
Shares in Virgin Galactic, Bill Holdings, Walt Disney Co, AstraZeneca, Topgolf Callaway, Allbirds, Bill Holdings, and Lyft shares were all…
…
AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate…
London (Reuters) - Der britische Pharmakonzern AstraZeneca erhöht dank starker Nachfrage nach seinen Krebsmedikamenten die Geschäftsziele für dieses Jahr.
Für…
CAMBRIDGE (dpa-AFX) - Astrazeneca hat den Umsatzschwund bei Covid-Arzneien auch im dritten Quartal gut verkraftet.…
AstraZeneca lifts full-year guidance for EPS, revenue despite profit miss…
…
AstraZeneca Plc raised its profit outlook for the year and clinched a deal to develop a drug from the pharma…
09 November 2023
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III…